Brief: Icecure's Next-Generation Multiprobe Cryoablation Technology Issued Notice Of Allowance From Japan's Patent Office
25/11/2024 13:48
Nov 25 (Reuters) - Icecure Medical Ltd ICCM.O :
* ICECURE'S NEXT-GENERATION MULTIPROBE CRYOABLATION
TECHNOLOGY
ISSUED NOTICE OF ALLOWANCE FROM JAPAN'S PATENT OFFICE
* ICECURE MEDICAL LTD: TERUMO CORPORATION PLANS TO FILE FOR
REGULATORY APPROVAL OF PROSENSE FOR BREAST CANCER IN 2025
Source text: ID:nPnbtmRjCa
Further company coverage: ICCM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Icecure Medical
See all newsIcecure Medical Ltd reports results for the quarter ended June 30 - Earnings Summary
Israel's IceCure Medical H1 revenue rises on higher system, probe sales
Brief: Icecure Sio Petitions Nccn To Include Cryoablation In Breast Cancer Treatment Guidelines, Citing Icecure's FDA Clearance Of Prosense®
NASDAQ RESUMED AT 09:55 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:45 AM